15 studies found for:    polo-like kinase
Show Display Options
Rank Status Study
1 Active, not recruiting Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Other: Tissue Collection
2 Recruiting A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: CFI-400945
3 Completed Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumor;   Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Drug: GSK461364
4 Completed A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Conditions: Cancer;   Neuroendocrine Tumors;   NET;   Adrenocortical Carcinoma;   ACC
Intervention: Drug: TKM-080301
5 Completed Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Intervention: Drug: NMS-1286937
6 Terminated
Has Results
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
Condition: Advanced Nonhematological Malignancies
Intervention: Drug: TAK-960
7 Completed
Has Results
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727
8 Not yet recruiting Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vincristine Sulfate Liposome;   Drug: Volasertib
9 Not yet recruiting Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Conditions: Relapsed and Refractory Aggressive B- and T-cell Lymphomas;   Lymphoma
Interventions: Drug: volasertib;   Drug: belinostat
10 Completed Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatoma;   Liver Cancer, Adult;   Liver Cell Carcinoma, Adult
Intervention: Drug: TKM-080301
11 Completed Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Drug: BI 2536
12 Completed TKM 080301 for Primary or Secondary Liver Cancer
Conditions: Colorectal Cancer With Hepatic Metastases;   Pancreas Cancer With Hepatic Metastase;   Gastric Cancer With Hepatic Metastase;   Breast Cancer With Hepatic Metastase;   Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
13 Not yet recruiting A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
Conditions: Leukemia, Myeloid, Acute;   Leukemia, Monocytic, Acute;   Leukemia, Myelomonocytic, Acute;   Leukemia, Erythroblastic, Acute;   Leukemia, Megakaryoblastic, Acute
Interventions: Drug: Volasertib;   Drug: Idarubicin;   Drug: Cytarabine
14 Completed BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Condition: Neoplasms
Interventions: Drug: Volasertib, low dose, d1q3w;   Drug: Volasertib, middle dose, d1q3w;   Drug: Volasertib, high dose, d1q3w
15 Completed BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Condition: Neoplasms
Intervention: Drug: BI 6727

Indicates status has not been verified in more than two years